Track market-moving stories before they get noisy

Posted by Defense World Staff on Aug 8th, 2026

Empowered Funds LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report) by 515.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,601 shares of the medical instruments supplier’s stock after acquiring an additional 106,024 shares during the quarter. Empowered Funds LLC owned approximately 0.06% of DENTSPLY SIRONA worth $1,469,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. First Eagle Investment Management LLC grew its position in shares of DENTSPLY SIRONA by 3.2% in the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after buying an additional 458,744 shares during the last quarter. AQR Capital Management LLC boosted its holdings in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock worth $129,445,000 after acquiring an additional 92,868 shares in the last quarter. Southpoint Capital Advisors LP purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $116,000,000. Finally, Armistice Capital LLC raised its holdings in shares of DENTSPLY SIRONA by 27.2% in the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock worth $83,416,000 after buying an additional 1,562,000 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

Insider Activity at DENTSPLY SIRONA In other news, Director Brian P. Mckeon purchased 10,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brian T. Gladden acquired 9,985 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was acquired at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at $619,726.98. The trade was a 19.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth Several analysts have weighed in on the company. Citigroup initiated coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday. Mizuho dropped their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Barclays cut their price objective on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Finally, UBS Group decreased their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.54.

Read Our Latest Stock Report on XRAY

DENTSPLY SIRONA Stock Down 8.0% Shares of NASDAQ XRAY opened at $12.12 on Friday. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -4.41, a price-to-earnings-growth ratio of 1.57 and a beta of 0.85. The company’s 50-day simple moving average is $11.77 and its 200-day simple moving average is $11.89. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.74%. The company’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.

DENTSPLY SIRONA News Summary Here are the key news stories impacting DENTSPLY SIRONA this week:

Positive Sentiment: Adjusted earnings exceeded expectations: Q2 EPS was $0.52, above analyst estimates ranging from $0.35 to $0.36 and matching the year-ago result. Revenue of $898 million also surpassed the roughly $890 million consensus. Dentsply International Beats Q2 Earnings and Revenue Estimates Positive Sentiment: Margins improved: Management highlighted better margins during the quarter, helping offset softer demand and supporting the earnings beat. The Wellspect business was a key sales-growth contributor. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales Neutral Sentiment: Full-year EPS guidance was maintained: DENTSPLY SIRONA reiterated 2026 adjusted EPS guidance of $1.40 to $1.50, which brackets the approximately $1.42 analyst consensus. DENTSPLY SIRONA Second-Quarter 2026 Results Negative Sentiment: Sales declined year over year: Q2 revenue fell 4.1%, as weakness in the company’s core dental business outweighed growth at Wellspect. This suggests that broader dental-market demand and utilization remain pressured. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales Negative Sentiment: Revenue guidance was cautious: The company forecast 2026 revenue of $3.5 billion to $3.6 billion, with the midpoint below the $3.6 billion consensus estimate. Investors appear to be prioritizing the weak organic-sales trend and outlook over the quarterly EPS beat. DENTSPLY SIRONA Company Profile (Free Report)

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

Recommended Stories Five stocks we like better than DENTSPLY SIRONA Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDai ichi Life Insurance Company Ltd Acquires 12,401 Shares of Amazon.com, Inc. $AMZN

NEXT HEADLINE »Empowered Funds LLC Raises Holdings in Snap Inc. $SNAP

Key Takeaways XRAY is expected to post Q2 revenues near $884 million and adjusted EPS of 36 cents.Transformation spending, dealer inventory cuts and tariffs may pressure near-term profitability.Wellspect growth and resilient APAC demand may offset weakness in equipment, implants and Europe. DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release second-quarter 2026 results on Aug. 6, after market close.

In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 3.57%. It delivered an average earnings surprise of negative 5.23% for the trailing four quarters.

XRAY’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $883.9 million. The consensus mark for earnings is pinned at 36 cents per share.

Our model estimates for revenues and adjusted earnings per share (EPS) are $884.8 million and 36 cents, respectively.

Factors to Note Ahead of XRAY’s Q2 ResultsDENTSPLY SIRONA's second-quarter 2026 performance is likely to have reflected continued execution of its Return-to-Growth action plan. The company remains focused on commercial restructuring, clinical education, innovation and cost optimization during the second quarter. While these initiatives are expected to strengthen long-term growth, they are likely to have weighed on near-term profitability due to higher investments. Per the first-quarter earnings call, management also indicated that meaningful benefits from the transformation plan are expected to build gradually, with a larger impact in the second half of 2026.

The second quarter is also likely to have been affected by dealer inventory adjustments linked to the transition toward a drop-ship model. Management expects this inventory burn to occur primarily from the second quarter through the remainder of the year. This dynamic is likely to have created a revenue headwind, particularly across equipment and connected technology products. Tariff-related costs, softer implant demand and continued weakness in certain European markets are also expected to have remained pressure points during the quarter.

From a segmental standpoint, Connected Technology Solutions is likely to have remained under pressure due to softer equipment demand and dealer inventory normalization. Orthodontic and implant sales may also have stayed weak as the company continues to rebuild commercial execution in these businesses. However, Wellspect Healthcare is expected to have maintained healthy growth, supported by new product adoption. Essential Dental Solutions could also have benefited if dealer destocking trends in Europe began to moderate, as management expects.

Geographically, the U.S. business is likely to have remained the company's primary focus. Management has been expanding distributor partnerships, strengthening its sales organization and increasing customer engagement to restore growth. International markets, particularly APAC, are expected to have remained relatively resilient, while Europe is likely to have faced some pressure from inventory destocking and macro uncertainty in the to-be-reported quarter.

Investors are likely to closely watch management's commentary on the pace of U.S. recovery, dealer inventory normalization and traction from new distribution agreements. Updates on the implants turnaround, commercial execution and early adoption of recently launched products will also be in focus. Any indication that restructuring savings and revenue initiatives are beginning to contribute meaningfully in the second half of 2026 could improve investor sentiment.

What the Zacks Model Unveils for XRAYOur proven model does not conclusively predict an earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.

XRAY’s Earnings ESP:Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

XRAY’s Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #3.

Stocks to ConsiderHere are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.

Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rank stocks here.

CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.

Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release third-quarter fiscal 2026 results on Aug. 5.

COR’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 1.59%. The Zacks Consensus Estimate for COR’s fiscal third-quarter EPS implies an improvement of 9.3% from the year-ago reported figure.

Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank #2 at present.

A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.